{"id":"NCT01709084","sponsor":"Janssen-Cilag International NV","briefTitle":"A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment","officialTitle":"A Phase 3b, Randomized, Open-label Clinical Study to Demonstrate Non-inferiority in Virologic Response Rates of HIV-1 RNA Suppression <400 Copies/mL of TDF/FTC/RPV Versus TDF/FTC/EFV in First-line Antiretroviral NNRTI-based Suppressed Patients. Switching At Low HIV-1 RNA Into Fixed Dose Combinations (SALIF)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-10-02","primaryCompletion":"2015-10-22","completion":"2020-07-02","firstPosted":"2012-10-17","resultsPosted":"2017-01-05","lastUpdate":"2021-02-11"},"enrollment":426,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Human Immunodeficiency Virus-type 1 Infection"],"interventions":[{"type":"DRUG","name":"Rilpivirine","otherNames":["EDURANT"]},{"type":"DRUG","name":"Efavirenz","otherNames":[]},{"type":"DRUG","name":"Tenofovir disoproxil fumarate","otherNames":[]},{"type":"DRUG","name":"Emtricitabine","otherNames":[]}],"arms":[{"label":"Group 1","type":"EXPERIMENTAL"},{"label":"Group 2","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to demonstrate noninferiority (a new treatment is equivalent to standard treatment) in terms of the percentage of patients who have plasma human immunodeficiency virus-type 1 (HIV-1) ribonucleic acid (RNA) levels less than 400 copies per mL after 48 weeks of randomized treatment with tenofovir disoproxil fumarate/emtricitabine/rilpivirine (TDF/FTC/RPV) versus TDF/FTC/efavirenz (TDF/FTC/EFV).","primaryOutcome":{"measure":"Percentage of Participants With Plasma Human Immunodeficiency Virus - Type 1 Ribonucleic Acid (HIV-1 RNA) Levels Less Than (<) 400 Copies Per Milliliter (Copies/mL) at Week 48","timeFrame":"Week 48","effectByArm":[{"arm":"TDF/FTC/RPV","deltaMin":93.9,"sd":null},{"arm":"TDF/FTC/EFV","deltaMin":96.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":18,"countries":["Cameroon","Kenya","Senegal","South Africa","Thailand","Uganda"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":213},"commonTop":["Upper Respiratory Tract Infection","Headache","Urinary Tract Infection","Back Pain","Malaria"]}}